Dermata insider reports 19.6% ownership stake

Dermata Therapeutics insider Gerald T. Proehl reports beneficial ownership of 694,576 shares of common stock, representing 19.6% of the company’s outstanding shares as of January 29, 2026.

Rhea-AI Filing Summary

Dermata Therapeutics insider Gerald T. Proehl reports beneficial ownership of 694,576 shares of common stock, representing 19.6% of the company’s outstanding shares as of January 29, 2026. This percentage is based on 3,549,393 shares outstanding on that date.

The stake includes 24 shares and options for 1,763 shares held directly, 79,950 shares and 11 warrant shares held through Proehl Investment Ventures LLC, and 612,828 shares held by certain trusts where he is trustee. Some additional options and warrants are excluded because they do not vest or become exercisable within sixty days or require stockholder approval.

The filing states there have been no purchases or sales of Dermata common stock or related convertible securities by Proehl or entities he controls since the prior amendment filed on January 8, 2026.

FAQ

How many Dermata Therapeutics (DRMA) shares does Gerald T. Proehl beneficially own?

Gerald T. Proehl may be deemed to beneficially own 694,576 shares of Dermata common stock. This total includes direct holdings, options, LLC-held shares, and shares in certain trusts for which he serves as trustee, as detailed in the ownership breakdown.

What percentage of Dermata Therapeutics (DRMA) does Gerald T. Proehl own?

Proehl may be deemed to beneficially own 19.6% of Dermata’s common stock. This percentage is calculated using 3,549,393 shares outstanding as of January 29, 2026, based on information obtained from the company and disclosed in the filing.

How is Gerald T. Proehl’s Dermata (DRMA) ownership stake structured?

His 694,576-share beneficial stake includes 24 shares and options for 1,763 shares held directly, 79,950 shares and 11 warrant shares held by Proehl Investment Ventures LLC, and 612,828 shares held by certain trusts for which he acts as trustee.

Were there recent Dermata (DRMA) share transactions by Gerald T. Proehl?

The filing states there were no purchases or sales of Dermata common stock, or securities convertible into or exchangeable for common stock, by Proehl or entities he controls since Amendment No. 8, which was filed on January 8, 2026.

Which Dermata (DRMA) options and warrants are excluded from Proehl’s reported ownership?

Excluded are 41,070 option shares that will not vest within sixty days and 78,740 warrant shares not exercisable within sixty days. The warrants become exercisable only after Dermata obtains stockholder approval of the transaction in which those warrants were issued.

Does Gerald T. Proehl have sole voting power over his Dermata (DRMA) shares?

Yes. The filing reports that Proehl has sole voting and sole dispositive power over all 694,576 Dermata shares he may be deemed to beneficially own, with no shared voting or shared dispositive power reported for this stake.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 06:35 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 9)

Dermata Therapeutics, Inc.

(Name of Issuer)

Common Stock, Par Value $0.0001 Per Share.

(Title of Class of Securities)

249845504

(CUSIP Number)

Gerald T. Proehl
President and Chief Executive Officer,, 3525 Del Mar Heights Rd., #322
San Diego, CA, 92130
(973) 701-2431

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/29/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 249845504

1

Name of reporting person

PROEHL GERALD T

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 694,576.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 694,576.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

694,576.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

19.6 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 5 for additional information.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, Par Value $0.0001 Per Share.
(b)	Name of Issuer: Dermata Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3525 Del Mar Heights Rd., #322, San Diego, CALIFORNIA , 92130.
Item 1 Comment: This Amendment No. 9 (this "Amendment") amends and supplements the Schedule 13D filed on behalf of the Reporting Persons with the Securities and Exchange Commission on August 27, 2021, as amended on April 25, 2022, January 13, 2023, March 30, 2023, January 23, 2025, February 13, 2025, April 3, 2025, April 7, 2025, and January 8, 2026 (collectively, the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Schedule 13D and the information set forth in or incorporated by reference in Item 2 and Item 3 of the Schedule 13D is hereby incorporated by reference in its entirety into this Item 5. As of the date hereof, Mr. Proehl may be deemed to beneficially own an aggregate of 694,576 shares of Common Stock reported herein as follows: (i) 24 shares of Common Stock and stock options to purchase 1,763 shares of Common Stock held directly by Mr. Proehl; (ii) 79,950 shares of Common Stock and 11 shares of Common Stock underlying warrants that are exercisable within sixty (60) days of the date hereof held by Proehl Investment Ventures LLC ("PIV"); and (iii) 612,828 shares of Common Stock held in the aggregate by certain trusts (the "Trusts") for which Mr. Proehl is trustee. Mr. Proehl's reported ownership excludes (i) 41,070 shares of Common Stock underlying stock options held by Mr. Proehl that will not vest as to such shares of Common Stock within sixty (60) days of the date hereof; and (ii) 78,740 shares of Common Stock underlying warrants that are not exercisable within sixty (60) days of the date hereof. The warrants reported in (ii) above are not exercisable until the Issuer obtains stockholder approval of the transaction in which such warrants were issued. As a result of the foregoing, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Mr. Proehl may be deemed to beneficially own 19.6% of the Common Stock of the Issuer outstanding as of the date hereof (based on 3,549,393 shares of Common Stock outstanding as of January 29, 2026 based on information obtained from the Issuer).
(b)	As of the date hereof, Mr. Proehl may be deemed to be the beneficial owner of an aggregate of 694,576 shares of Common stock, all of which he has sole voting and dispositive power.
(c)	Since Amendment No. 8 to this Schedule 13D (filed on January 8, 2026), there were no purchases or sales of shares of Common Stock, or securities convertible into or exchangeable for shares of Common Stock, by the Reporting Person or any person or entity for which the Reporting Person possess voting or dispositive control over the securities thereof.
(d)	None.
(e)	None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PROEHL GERALD T

Signature:	/s/ Gerald T. Proehl
Name/Title:	Gerald T. Proehl
Date:	02/02/2026